[go: up one dir, main page]

BRPI0511135A - formulação de aerossol para a inalação de beta-agonistas - Google Patents

formulação de aerossol para a inalação de beta-agonistas

Info

Publication number
BRPI0511135A
BRPI0511135A BRPI0511135-8A BRPI0511135A BRPI0511135A BR PI0511135 A BRPI0511135 A BR PI0511135A BR PI0511135 A BRPI0511135 A BR PI0511135A BR PI0511135 A BRPI0511135 A BR PI0511135A
Authority
BR
Brazil
Prior art keywords
inhalation
aerosol formulation
agonists
beta
propellant
Prior art date
Application number
BRPI0511135-8A
Other languages
English (en)
Inventor
Michael Aven
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34979667&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0511135(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of BRPI0511135A publication Critical patent/BRPI0511135A/pt
Publication of BRPI0511135B1 publication Critical patent/BRPI0511135B1/pt
Publication of BRPI0511135B8 publication Critical patent/BRPI0511135B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

FORMULAçãO DE AEROSSOL PARA A INALAçãO DE BETA-AGONISTAS. A presente invenção refere-se a uma formulação de aerossol isenta de gás propulsor, que compreende um ou mais compostos da fórmula geral 1 na qual os radicais R¬ 1¬, R¬ 2¬, R¬ 3¬ e X podem ter os significados citados na descrição, para a inalação.
BRPI0511135A 2004-05-14 2005-05-10 formulação de aerossol para a inalação de beta-agonistas BRPI0511135B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004024452A DE102004024452A1 (de) 2004-05-14 2004-05-14 Aerosolformulierung für die Inhalation von Betaagonisten
PCT/EP2005/005028 WO2005110421A2 (de) 2004-05-14 2005-05-10 Aerosolformulierung für die inhalation von betaagonisten

Publications (3)

Publication Number Publication Date
BRPI0511135A true BRPI0511135A (pt) 2007-11-27
BRPI0511135B1 BRPI0511135B1 (pt) 2019-11-12
BRPI0511135B8 BRPI0511135B8 (pt) 2021-05-25

Family

ID=34979667

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0511135A BRPI0511135B8 (pt) 2004-05-14 2005-05-10 formulação de aerossol para a inalação de beta-agonistas

Country Status (26)

Country Link
EP (1) EP1809293B1 (pt)
JP (1) JP4620730B2 (pt)
KR (1) KR101288791B1 (pt)
CN (1) CN101056640A (pt)
AR (1) AR049096A1 (pt)
AU (1) AU2005244414B2 (pt)
BR (1) BRPI0511135B8 (pt)
CA (1) CA2564379C (pt)
DE (1) DE102004024452A1 (pt)
DK (1) DK1809293T3 (pt)
EA (1) EA012583B1 (pt)
EC (1) ECSP067004A (pt)
ES (1) ES2575925T3 (pt)
HU (1) HUE027780T2 (pt)
IL (1) IL179218A (pt)
MX (1) MXPA06013216A (pt)
MY (1) MY148403A (pt)
NO (1) NO20065030L (pt)
PE (1) PE20060311A1 (pt)
PL (1) PL1809293T3 (pt)
SG (1) SG152265A1 (pt)
TW (1) TWI356703B (pt)
UA (1) UA87312C2 (pt)
UY (1) UY28891A1 (pt)
WO (1) WO2005110421A2 (pt)
ZA (1) ZA200607462B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
US7220742B2 (en) 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
DK1917253T3 (da) 2005-08-15 2015-03-30 Boehringer Ingelheim Int Fremgangsmåde til fremstilling af betamimetika
EP1948186A1 (en) * 2005-11-09 2008-07-30 Boehringer Ingelheim International Gmbh Aerosolformulation for inhalation
UY30543A1 (es) * 2006-08-18 2008-03-31 Boehringer Ingelheim Int Formulacion de aerosol para la inhalacion de beta- agonistas
WO2010057927A1 (en) * 2008-11-21 2010-05-27 Boehringer Ingelheim International Gmbh Aerosol formulation for the inhalation of beta agonists
JP2012509299A (ja) * 2008-11-21 2012-04-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング β作用薬吸入用のエアロゾル製剤
JP2015533131A (ja) 2012-10-09 2015-11-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 咳を治療するためのベータ２−アドレナリン受容体作動薬
US20200069679A1 (en) 2016-12-12 2020-03-05 Boehringer Ingelheim International Gmbh Nintedanib for use in methods for the treatment of interstitial lung diseases by coadministration with oladaterol
US20230095589A1 (en) * 2019-12-05 2023-03-30 Syngenta Crop Protection Ag One step process for the preparation of phenyl ethyl amine derivatives

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3134590A1 (de) * 1981-09-01 1983-03-10 Boehringer Ingelheim KG, 6507 Ingelheim Neue benzo-heterocyclen
US4460581A (en) * 1982-10-12 1984-07-17 Boehringer Ingelheim Kg (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones
JPH0637388B2 (ja) * 1986-02-17 1994-05-18 千寿製薬株式会社 水性液剤
GB9405019D0 (en) * 1994-03-15 1994-04-27 Smithkline Beecham Plc Novel compounds
DE10253282A1 (de) * 2002-11-15 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung
DE102004019539A1 (de) * 2004-04-22 2005-11-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von Atemwegserkrankungen
NZ550797A (en) * 2004-04-22 2010-08-27 Boehringer Ingelheim Int Pharmaceutical combinations containing 6-hydroxy-8-{1-hydroxy-2-[2-(4-methoxy-phenyl)-1,1-dimethylethylamino]-ethyl}-4H-benzo[1,4]oxazin-3-one for treating respiratory diseases
DE102004024454A1 (de) * 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Enantiomerenreine Betaagonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE102004024451A1 (de) * 2004-05-14 2005-12-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverformulierungen für die Inhalation, die Enantiomerenreine Betaagonisten enthalten

Also Published As

Publication number Publication date
ES2575925T3 (es) 2016-07-04
PE20060311A1 (es) 2006-05-08
IL179218A (en) 2012-10-31
CA2564379A1 (en) 2005-11-24
CN101056640A (zh) 2007-10-17
EA200602017A1 (ru) 2007-06-29
JP4620730B2 (ja) 2011-01-26
DE102004024452A1 (de) 2005-12-08
PL1809293T3 (pl) 2016-09-30
BRPI0511135B1 (pt) 2019-11-12
UY28891A1 (es) 2005-12-30
CA2564379C (en) 2013-07-30
IL179218A0 (en) 2007-03-08
ECSP067004A (es) 2007-02-28
MXPA06013216A (es) 2007-02-08
NO20065030L (no) 2006-11-30
HUE027780T2 (en) 2016-11-28
AU2005244414A1 (en) 2005-11-24
ZA200607462B (en) 2008-06-25
SG152265A1 (en) 2009-05-29
KR20070022084A (ko) 2007-02-23
WO2005110421A3 (de) 2006-03-16
TW200608981A (en) 2006-03-16
BRPI0511135B8 (pt) 2021-05-25
UA87312C2 (ru) 2009-07-10
JP2007537188A (ja) 2007-12-20
EA012583B1 (ru) 2009-10-30
EP1809293B1 (de) 2016-03-16
AU2005244414B2 (en) 2010-12-09
WO2005110421A2 (de) 2005-11-24
DK1809293T3 (en) 2016-06-20
AR049096A1 (es) 2006-06-28
EP1809293A2 (de) 2007-07-25
KR101288791B1 (ko) 2013-07-29
MY148403A (en) 2013-04-30
TWI356703B (en) 2012-01-21

Similar Documents

Publication Publication Date Title
BRPI0412029A (pt) formulações para microprojeções revestidas contendo contra-ìons não-voláteis
BR112014014410A2 (pt) composições e métodos que compreendem uma variante de enzima lipolítica
BR112014004444A2 (pt) composições e métodos que compreendem uma variante de enzima lipolítica
BRPI0713777B8 (pt) processo para preparação de formulações de pó seco de um sal de glicopirrônio para inalação
BRPI0609121B8 (pt) 1h-benzimidazol-4-carboxamidas substituídas com um carbono quaternário na posição 2
GT200600194A (es) Composiciones farmaceuticas conteniendo imatinib y un componente de liberacion prolongada
BRPI0610108B8 (pt) compostos promotores de apoptose e composição que compreende os ditos compostos
ECSP099750A (es) Imidazoquinolinas con propiedades inmunomoduladoras
BRPI0717907A2 (pt) "composto, composição farmacêutica, métodos para tratar um câncer, para inbir ou modular a atividade da lipídeo quinase, processo para a produçãoo de uma composição farmacêutica, uso de um composto e kit"
CR11106A (es) Inhibidores de cinasa p710 s6
NI201000055A (es) 2' - fluoro - 2' - desoxitetrahidrouridinas como inhibidores de citidina desaminasa.
WO2006138660A3 (en) Sphingosine kinase inhibitors
UY30942A1 (es) Nuevos derivados de 3-([1,2,4,]triazolo[4,3-a]piridin-7-il)benzamida
BRPI0408561A (pt) métodos para manufatura de 2'-desoxi-59-l-nucleosìeos
BRPI0508540B8 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0618479A2 (pt) pirrolpiridinas composição farmacêutica que as contém
BRPI0411367A (pt) composições oftálmicas contendo uma combinação sinergìstica de três polìmeros
BRPI0511135A (pt) formulação de aerossol para a inalação de beta-agonistas
AR062425A1 (es) Formulacion de aerosol para la inhalacion de agonistas beta
BRPI0508125A (pt) formulação de alcalóide, método para melhorar a eficácia de um alcalóide, uso do produto da reação de um ou mais alcalóides com um mais derivados de fosfato de um ou mais agentes de transferência de elétrons, junto com excipientes e composição farmacêutica
BRPI0712889A8 (pt) composto, processo para a preparação de um composto, composto intermediário, e, composição farmacêutica.
BR112021015771A2 (pt) Composição nutricional para lactentes ou crianças de primeira infância e uso da composição nutricional
BRPI0609765A8 (pt) mistura de isoalcano, método para a preparação da mesma, composição cosmética ou farmacêutica, e, uso de uma mistura de isoalcano
BR112015011515A2 (pt) Composições farmacêuticas de inibidores de cetp
CR7956A (es) Oxazolidinonas de indolona antibacterial intermedios para su preparacion y composiciones farmaceuticas que contienen los mismos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/11/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/11/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/05/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF